CORV - カルディオ―ム・ファ―マ (Correvio Pharma Corp.)

CORVのニュース

   TOP RANKED ROSEN LAW FIRM Reminds Correvio Pharma Corp. Investors of Important Deadline in Securities Action– CORV  2019/12/24 16:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Correvio Pharma Corp. (NASDAQ: CORV) between October 23, 2018 and December 5, 2019, inclusive (the “Class Period”) of the important February 10, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Correvio investors under the federal securities laws. To join the Correvio class action, go to http://www.rosenlegal.com/cases-register-17
   Correvio Pharma : Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events | MarketScreener  2019/12/24 13:01:04 MarketScreener
NASDAQ: CORV TSX: CORV VANCOUVER, Dec. 24, 2019 /PRNewswire/ - Correvio Pharma Corp. , a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it… | December 24, 2019
   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Correvio Pharma Corporation Investors  2019/12/23 21:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CORV--Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Correvio Pharma Corporation Investors
   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Correvio Pharma Corporation Investors  2019/12/19 19:30:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CORV--Glancy Prongay & Murray LLP Announces Investigation on Behalf of Correvio Pharma Corporation Investors
   Shareholder Alert: Robbins LLP Announces Correvio Pharma Corp. (CORV) Sued for Misleading Shareholders  2019/12/16 22:36:00 Business Wire
SAN DIEGO & VANCOUVER, Canada--(BUSINESS WIRE)---- $CORV #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Correvio Pharma Corp. (NASDAQ: CORV) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between October 23, 2018 and December 5, 2019. Correvio is a specialty pharmaceutical company that engages in developing therapeutics worldwide. The Company's brand portfolio includes Brinavess, used for the rapid conversion of recent onset atrial fib
  Glancy Prongay&Murray LLPは、Correvio Pharma Corporationの投資家に代わって調査を発表します」 Glancy Prongay & Murray LLP Announces Investigation on Behalf of Correvio Pharma Corporation Investors  2019/12/19 19:30:00 Business Wire
「ロサンゼルス-(ビジネスワイヤ)---- $ CORV--Glancy Prongay&Murray LLPは、Correvio Pharma Corporation Investorsに代わって調査を発表します
LOS ANGELES--(BUSINESS WIRE)---- $CORV--Glancy Prongay & Murray LLP Announces Investigation on Behalf of Correvio Pharma Corporation Investors
   Shareholder Alert: Robbins LLP Announces Correvio Pharma Corp. (CORV) Sued for Misleading Shareholders  2019/12/16 22:36:00 Business Wire
SAN DIEGO & VANCOUVER, Canada--(BUSINESS WIRE)---- $CORV #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Correvio Pharma Corp. (NASDAQ: CORV) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between October 23, 2018 and December 5, 2019. Correvio is a specialty pharmaceutical company that engages in developing therapeutics worldwide. The Company's brand portfolio includes Brinavess, used for the rapid conversion of recent onset atrial fib
   The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer  2019/12/13 13:10:02 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) (received approval for its bone-building osteoporosis drug in the U.S.) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Avenue Therapeutics Inc (NASDAQ: ATXI ) (submitted the NDA for intravenous tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting) Bausch Health Companies Inc (NYSE: BHC ) (reacted to upgrade to Overweight rating by JPMorgan) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Boston Scientific Corporation (NYSE: BSX ) Bristol-Myers Squibb Co (NYSE: BMY ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) Globus Medical Inc (NYSE: GMED ) (reacted to upgrade to Overweight by Wells Fargo Securities) Gossamer Bio Inc (NASDAQ: GOSS ) Hologic, Inc.
   CORREVIO PHARMA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Correvio Pharma Corp. and Encourages Investors to Contact the Firm  2019/12/13 00:15:00 Business Wire
NEW YORK--(BUSINESS WIRE)-- #classaction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased Correvio Pharma Corp. (NASDAQ: CORV) securities between October 23, 2018 and December 5, 2019 (the “Class Period”). Investors have until February 10, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit. C
   IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Correvio Pharma Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm  2019/12/12 21:42:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CORV #CORV--IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Correvio Pharma Corp.
   Correvio Pharma Corp. (CORV) CEO Mark Corrigan on Q1 2019 Results - Earnings Call Transcript  2019-05-11
Correvio Pharma Corp. (CORV) Q1 2019 Earnings Conference Call May 07, 2019 08:30 AM ET Company Participants Mark Corrigan - CEO Justin Renz - President and CFO Conference Call Participants Dewey Steadman - Canaccord Presentation Operator Good morning, ladies and gen…

calendar